Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is accelerating high-impact biomedical technologies to patients through partnerships with medical device companies, highlighted by their flagship product candidates Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon for arterial disease. They are focused on completing enrollment in their BACKBEAT study by 3Q26 and expect FDA approval and potential breakthrough designation to expand the target patient population. While the company faces commercialization risks, they have a strong cash balance and partnerships with industry leaders to support their product launches.

Bears say

Orchestra BioMed Hldgs is a high-risk investment with a negative outlook due to limited human clinical data, potential for failure of product candidates in clinical trials, and dependence on partnerships for commercialization. Its valuation of $595 million is based on a discounted cash flow analysis and assumes a probability of success of 65% and 40% for its product candidates. Risks to achieving the price target include potential dilution, regulatory delays or denials, and the need for additional funding.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.